Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06914648 · ClinicalTrials.gov registry record · NA
The Dragon PLC Trial (DRAGON-PLC)
A NA study of Cholangiocarcinoma and Hepatocellular Carcinoma (HCC), sponsored by Maastricht University.
- Recruiting
- Registry status
- NA
- Development phase
- 358
- Enrollment target
- 20
- Study locations
NCT06914648: Recruiting NA study of Cholangiocarcinoma and Hepatocellular Carcinoma (HCC), sponsored by Maastricht University.
NCT06914648 is a NA study of Cholangiocarcinoma and Hepatocellular Carcinoma (HCC) that is actively recruiting participants, run by Maastricht University. The registered enrollment target is 358 participants, roughly in line with the 380-participant average among 60 other Cholangiocarcinoma trials with a reported enrollment target. The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06914648, a NA study of Cholangiocarcinoma and Hepatocellular Carcinoma (HCC), is actively recruiting participants, sponsored by Maastricht University.
- RECRUITING
- Registry status
- NA
- Development phase
- 358 participants
- Enrollment target
- 20
- Study locations
Study Summary
The goal of the DRAGON PLC clinical trial is to determine whether portal vein embolization (PVE) combined with hepatic vein embolization (HVE) improves resectability and overall survival in patients with initially unresectable primary liver cancer compared to standard PVE alone. This trial specifically focuses on patients with hepatocellular carcinoma and cholangiocarcinoma. The main questions this trial aims to answer are whether combined PVE and HVE increases the proportion of patients who become resectable within 3 weeks and improves 5-year overall survival compared to PVE alone by enhancing liver hypertrophy. Participants will: * Undergo either standard PVE or combined PVE and HVE. * Have regular imaging to assess liver resectability. * Be monitored for survival outcomes up to 5 years after intervention.
Primary Outcome
The FLR is considered sufficient for resection 3 weeks after embolisation. Definition resectable: Patients are deemed resectable if the FLR is ≥30% in normally functioning livers, ≥40% in livers with potentially impaired function (e.g. resulting from prior systemic therapy or bile duct colonization / transpapillary biliary drainage), or ≥50% in livers with severely impaired function resulting from liver cirrhosis (max. Child Pugh A5) OR for any FLR volume, function on hepatobiliary scintigraphy
Conditions Studied
Interventions
- PROCEDURE Portal Vein Embolization
- PROCEDURE Hepatic Vein Embolization
Study Locations (20)
Other
- Monash Medical Center - Melbourne
- Cliniques Universitaires Saint Luc, UCLouvain - Brussels
- Jessa Hospital - Hasselt
- UZ Brussel - Jette
- AZ Groeninge Hospital Kortrijk - Kortrijk
Vienna
- Medical University of Vienna - Vienna
- Social Center South - Vienna
Connecticut
- Yale School of Medicine Hospital - New Haven
Illinois
- Rush University Medical Center - Chicago
Minnesota
- Mayo Clinic - Rochester
New York
- Memorial Sloan Kettering Cancer Center - New York
Ohio
- Cleveland Clinic - Cleveland
Brussels Capital
- Erasmus Hospital - Brussels
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 358 participants |
| Start Date | 2025-04-01 |
| Est. Completion | 2032-11-15 |
| Phase | NA |
What NCT06914648 shows while recruiting
NCT06914648 is an interventional study that assigns participants to a tested intervention. The registered 358 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 380-participant average among 60 other Cholangiocarcinoma trials with a reported enrollment target.
The record links to 3 conditions, with Cholangiocarcinoma appearing as the primary indexed condition, and to 2 interventions - of which Portal Vein Embolization is the first listed.
NCT06914648 names 20 study sites across 15 states, led by Other, Vienna, Connecticut.
Frequently Asked Questions
What is clinical trial NCT06914648 about?
NCT06914648 is a clinical study titled "The Dragon PLC Trial (DRAGON-PLC)". The goal of the DRAGON PLC clinical trial is to determine whether portal vein embolization (PVE) combined with hepatic vein embolization (HVE) improves resectability and overall survival in patients with initially unresectable primary liver cancer compared to standard PVE alone. This trial specifica...
What is the current status of trial NCT06914648?
This trial is currently recruiting. It is a NA study. The enrollment target is 358 participants. The study started on 2025-04-01. Estimated completion is 2032-11-15.
What conditions does trial NCT06914648 study?
This clinical trial studies the following conditions: Cholangiocarcinoma, Hepatocellular Carcinoma (HCC), Primary Liver Cancer.
What interventions are being tested in trial NCT06914648?
The interventions under investigation include: Portal Vein Embolization (PROCEDURE), Hepatic Vein Embolization (PROCEDURE).
Who is sponsoring clinical trial NCT06914648?
This trial is sponsored by Maastricht University, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06914648 being conducted?
This trial has 20 study locations across Connecticut, Illinois, Minnesota, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cholangiocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06914648's enrollment target sits among peer trials
358 13th of 60 higher than 48 of 60 other Cholangiocarcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cholangiocarcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Targeted Navigation in Hepatocellular Carcinoma (HCC)
RECRUITING · NA
-
HepQuant: Study to Assess the Role of Blood-based Biomarkers and Quantitative MR Imaging for Patients Receiving Radiation Therapy for Liver Cancer
RECRUITING · NA
-
High Volume Washing of the Abdomen in Increasing Survival After Surgery in Patients With Pancreatic Cancer That Can Be Removed by Surgery
RECRUITING · NA
-
Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers
RECRUITING · NA
-
Implementing a Randomized Control Trial to Test the Expanded Web-based Decision Aid
RECRUITING · NA
-
Washington University Participant Engagement and Cancer Genomic Sequencing Center (WU-PE-CGS)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04373317 · 358 participants · Phase 4
Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis
- NCT05684965 · 358 participants · Phase 1
XTX301 in Patients With Advanced Solid Tumors
- NCT05824975 · 358 participants · Phase 1
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
- NCT06480227 · 358 participants · NA
Trial of Transurethral Bulking Agent Injection Versus Single-Incision Sling for Stress Urinary Incontinence
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI